Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11483651
Bobrovskaya L, Odell A, Leal RB, Dunkley PR (2001) Tyrosine hydroxylase phosphorylation in bovine adrenal chromaffin cells: the role of MAPKs after angiotensin II stimulation. J Neurochem 78, 490-8 11483651
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S19-p - TH (cow)
Modsite: KGFRRAVsELDAKQA SwissProt Entrez-Gene
Orthologous residues
TH (human): S19‑p, TH iso2 (human): S19‑p, TH iso3 (human): S19‑p, TH iso4 (human): S19‑p, TH (mouse): S19‑p, TH (rat): S19‑p, TH (cow): S19‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase
SB203580 angiotensin inhibit treatment-induced increase
PD123319 angiotensin no effect upon treatment-induced increase
losartan angiotensin inhibit treatment-induced increase
PD98059 angiotensin no effect upon treatment-induced increase
U0126 angiotensin no effect upon treatment-induced increase
SB202474 angiotensin no effect upon treatment-induced increase
anisomycin increase
SB203580 anisomycin inhibit treatment-induced increase
SB203580 no change compared to control
PD123319 no change compared to control
losartan no change compared to control

S31-p - TH (cow)
Modsite: KQAEAIMsPRFVGRR SwissProt Entrez-Gene
Orthologous residues
TH (human): S62‑p, TH iso2 (human): S58‑p, TH iso3 (human): S31‑p, TH iso4 (human): S35‑p, TH (mouse): S31‑p, TH (rat): S31‑p, TH (cow): S31‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase
PD123319 angiotensin no effect upon treatment-induced increase
losartan angiotensin inhibit treatment-induced increase
SB203580 angiotensin inhibit treatment-induced increase
SB202474 angiotensin no effect upon treatment-induced increase
PD98059 angiotensin inhibit treatment-induced increase
U0126 angiotensin inhibit treatment-induced increase
anisomycin no change compared to control
SB203580 anisomycin no change compared to control
SB203580 no change compared to control
PD123319 no change compared to control
losartan no change compared to control

S40-p - TH (cow)
Modsite: RFVGRRQsLIQDARK SwissProt Entrez-Gene
Orthologous residues
TH (human): S71‑p, TH iso2 (human): S67‑p, TH iso3 (human): S40‑p, TH iso4 (human): S44‑p, TH (mouse): S40‑p, TH (rat): S40‑p, TH (cow): S40‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase
PD123319 angiotensin no effect upon treatment-induced increase
losartan angiotensin inhibit treatment-induced increase
PD98059 angiotensin no effect upon treatment-induced increase
U0126 angiotensin no effect upon treatment-induced increase
SB202474 angiotensin no effect upon treatment-induced increase
SB203580 angiotensin no effect upon treatment-induced increase
anisomycin no change compared to control
SB203580 anisomycin no change compared to control
SB203580 no change compared to control
losartan no change compared to control
PD123319 no change compared to control